DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (S1609)

Study Details

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

Learn More

ClinicalTrials.gov NCT number

NCT02834013

Principal Investigators

• Salvatore Del Prete, MD

Sponsor(s)

Southwest Oncology Group

Contact

Ed Hatton, RN at 203-358-8879
or officeofresearch@stamhealth.org